| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H23N7 |
| Molecular Weight | 253.3472 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)C1=NC(=NN)N=C(N1)N(CC)CC
InChI
InChIKey=IRQOBYXMACIFKD-UHFFFAOYSA-N
InChI=1S/C11H23N7/c1-5-17(6-2)10-13-9(16-12)14-11(15-10)18(7-3)8-4/h5-8,12H2,1-4H3,(H,13,14,15,16)
| Molecular Formula | C11H23N7 |
| Molecular Weight | 253.3472 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Meladrazine is a drug used in urology as an antispasmodic. Meladrazine acts on the central nervous system as a polysynaptic inhibitor. Its usefulness in treating spasticity in patients with multiple sclerosis is well known. As many of these patients have bladder problems, a coincidental beneficial effect on uninhibited bladders has been discovered. Meladrazine caused a high incidence of side effects; therefore, treatment with terodiline separately is recommended for geriatric patients who have severe motor urge incontinence.
